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A trial ﬁbrillation (AF) is a global health problem. Thecondition brings an increased risk of stroke, systemic
embolism, and heart failure (HF) and is associated with
impaired quality of life, frequent hospitalizations, and mortality.1
Observational studies have been the main source of
information for many years and have deﬁned the clinical
presentation, clinical course, and prognosis of AF. Based on
key issues identiﬁed by observational studies, management of
patients with AF has been informed by randomized, controlled
trials (RCTs) that provide the main support for guideline
recommendations regarding management of patients with AF
and prevention of thromboembolic complications. Neverthe-
less, important questions regarding the clinical course, risks,
and management of AF in clinical practice remain
unanswered.1
Although RCTs provide high-level evidence on the efﬁcacy
and safety of therapeutic interventions, they generally
involve well-deﬁned study populations that exclude complex
patients and have standardized protocols for management
with closer monitoring and stricter follow-up than is typical
of routine clinical practice. Thus, their results are not always
directly applicable to the general population or routine
practice.
Traditional observational studies, often limited to small
patient populations and performed at a single institution, are
giving way to multicenter and national registries, supported by
the transfer of information to large databases. Structured data
collection can inform the generation of new hypotheses and
help to test established ones. Registries are also subject to
limitations as well as potential confounding factors related to
the population selected, number, and scope of tracked
variables and prevailing concepts of the disease under
investigation.2 These difﬁculties have been highlighted by
expert groups that elaborated guidelines for reliable reporting
of observational studies.3
Study designs vary depending on whether the objectives
involve disease deﬁnition, diagnostic methodology, occur-
rence, etiology, prevention, prognosis, and treatment. The
information obtained from observational and interventional
studies provide different approaches that require integration
of a wide array of data to derive a complete perspective on a
disease or condition.
This review provides an overview of available registry data
on patients with AF and focuses on 3 areas at the heart of AF
management: (1) stroke prevention; (2) pharmacological
rhythm and rate control; and (3) catheter-based ablation. In
addition to cataloging the types of registry data available, we
consider how these data contribute to understanding and
management of patients with AF and speculate on the future
directions of observational research.
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CONTEMPORARY REVIEWS
The Search Strategy
Registries or databases reporting on AF management, iden-
tiﬁed from sources that included CINAHL, Medline, EMBASE,
and the Cochrane Database of Systematic Reviews from 2000
to 2012, were selected for closer review, and publications
from these registries were tracked. We identiﬁed 34 large
international or national registries of AF patients, including 17
reporting on thromboprophylaxis and stroke prevention, 8
focused on antiarrhythmic drug (AAD) therapy and cardiover-
sion, 7 studying AF ablation, and 2 detailing left atrial
appendage closure (LAAC) registries.
Cataloging AF Registries
Tables 1 through 4 provide overviews of the registries
identiﬁed, which have been grouped into the following
broad categories: (1) those focused on thromboprophylaxis
and stroke prevention (Table 1); (2) those on cardioversion
and AAD therapy (Table 2); (3) those on ablation (Table 3); and
LAAC (Table 4). Several registries address multiple aspects
of AF diagnosis and management and could be allocated to
more than 1 category. To enable some key ﬁndings to be
visualized more clearly, registries that provide information on
medical treatments for AF (including use of agents for rhythm
and rate control, warfarin, aspirin, and new oral anticoagulants
[NOACs]) are also shown separately in Table 5.
Thromboprophylaxis and Stroke Prevention
Registries
A number of registries provide data on management and
prevention of thromboembolism in hospitalized and ambula-
tory patients with AF, offering insights into the effectiveness
of oral anticoagulation (OAC) therapy (Table 1). Several large-
scale registries on OAC use have been initiated by the
pharmaceutical industry (Table 1) and focus on NOACs. For
example, the Global Anticoagulant Registry in the Field
(GARFIELD)7 and Global Registry on Long-term Oral Anti-
thrombotic Treatment in Patients with Atrial Fibrillation
(GLORIA-AF),8 which are observational, global, large-scale
prospective registries, assess patterns and outcomes of
thromboprophylaxis.
A number of national and regional registries address
medication preference by patients. The Adherence eValuation
After Ischemic Stroke Longitudinal (AVAIL) registry, for
example, expanded on the hospital-based Get with the
Guidelines-Stroke quality improvement program and Carotid
RX ACCULINK/RX ACCUNET Post-Approval Trial to Uncover
Unanticipated or Rare Events (CAPTURE), a prototype registry
from the Paul Coverdale National Acute Stroke Registry.4,5
These evaluate whether patient management accords with
practice guidelines and evidence-based research. The Nation-
wide Danish study,11 Outcomes Registry for Better Informed
Treatment of Atrial Fibrillation (ORBIT-AF)12 and Prevention of
thromboembolic events–European Registry in Atrial Fibrilla-
tion (PREFER-AF)13 registries address this in European and
U.S. patient cohorts. Data have been collected from each of
these with the exception of CAPTURE, GARFIELD, and ORBIT-
AF registries, which are ongoing.
Registries Reporting on AAD Therapy and
Cardioversion
Pharmacological and direct-current cardioversion of AF has
been charted by a number of registries to provide information
on global treatment patterns (Table 2). The global Registry on
Cardiac rhythm disorders assessing the control of Atrial
Fibrillation (RECORD-AF)25 was one of the ﬁrst world-wide
observational surveys of the management of patients with
newly diagnosed paroxysmal or persistent AF, and the Real
Life Global Survey Evaluating Patients with Atrial Fibrillation
(REALISE-AF)24 cross-sectional study captured data in 26
participating countries on AF management and cardiovascular
(CV) risk proﬁles. RECORD-AF has also been extended to
cover the Asia-Paciﬁc region (RECORD-AF Asia Paciﬁc).28 In
addition, RHYTHM-AF is an international prospective study
aimed at determining regional variability, outcomes, and cost-
effectiveness among patients with recent-onset AF consid-
ered for cardioversion in 10 countries of antiarrhythmic and
antithrombotic treatment.29 As shown in Table 2, other
smaller, national registries assessing AAD use and cardiover-
sion include US Atrial Fibrillation Focus on Effective Clinical
Treatment Strategies (AFFECTS),18 the German Outpatient
Registry Upon Morbidity of Atrial Fibrillation (ATRIUM)
registry,20 and the Canadian Registry of Atrial Fibrillation
(CARAF).21
Registries Reporting on AF Ablation and LAAC
Table 3 details registries assessing ablation therapy for AF.
The Atrial Fibrillation Ablation Pilot Study, a prospective,
multinational registry conducted by the European Heart
Rhythm Association of the European Society of Cardiology,31
was undertaken preceding a long-term Atrial Fibrillation
Ablation pan-European Registry by the Euro-observational
Research Programme, which opened in 2012 and invited
participation from clinical sites in 54 countries. To date, some
875 patients have been enrolled from 61 or 137 registered
centers in 19 or 29 registered nations. Table 3 describes
other registries on AF ablation, such as the Safety of Atrial
Fibrillation Ablation Registry Initiative (SAFARI),36organized by
the US Cardiac Safety Research Consortium (CSRC),39 and
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the CARAF program in Canada.21 In addition to AF ablation,
LAAC is under investigation as a potential alternative to
anticoagulation for patients at high risk of stroke in the
Amplatzer cardiac plug (ACP)37 and ASA Plavix Feasibility
Study With Watchman LAAC (ASAP)38 registries (Table 4).
Insights From Registries
Registries on Thromboprophylaxis and Stroke
Prevention
Stroke epidemiology and risk factors
Patients with AF are at risk of stroke and twice as likely to die
within 1 year as those without AF.40 The Euro Heart survey, in
which patients with AF (new in 18%, paroxysmal in 28%,
persistent in 22%, and permanent in 29%) had a mean age of
67 years and 26% older than 75 years, found that 86% were
at high risk for stroke.6
Data from the Nationwide Danish study highlight that
chronic kidney disease (CKD) in patients with AF is associated
with even greater risk of stroke or systemic embolism. In this
cohort, the risk of stroke or thromboembolism in patients with
CKD (hazard ratio, 1.49) was signiﬁcantly lower in patients
treated with warfarin.41 Reports from this registry also note
higher risk of bleeding among patients with CKD treated with
warfarin, aspirin, or both.42 Bleeding risks associated with
OACs are a potential disadvantage of therapy, but data from
registries help identify patients most likely to encounter
bleeding complications. The concept of “net clinical beneﬁt”
aims to balance the risks of ischemic stroke and bleeding on
OAC therapy43 and was originally tested using U.S. registry
data. This concept, used to compare NOACs and warfarin,
have been facilitated by registry data.11,44 Banerjee et al.
used “real-world” data on net clinical beneﬁt of warfarin from
the Danish National Patient Registry and modeled the
expected net clinical beneﬁt for NOACs (dabigatran, rivarox-
aban, and apixaban) on the basis of recent clinical trial
outcomes.11 The ﬁndings indicated that when there is a high
risk of both ischemic stroke and intracranial hemorrhage, all 3
of the new agents have a greater net clinical beneﬁt,
compared to warfarin (Figure).45,46
Registry ﬁndings, such as those from Denmark and
Sweden (Table 1), have helped develop and reﬁne risk-scoring
systems for stroke and bleeding in AF patient cohorts.17,41
Scoring systems such as CHADS2 and CHA2DS2-VASc have
changed the approach to risk stratiﬁcation of AF patients and
guide judicious use of OAC in patients at greatest risk.47,48
Registry data have been crucial in deriving risk stratiﬁcation
schemes and validating the utility in clinical practice.48–50
Both the CHADS2 and CHA2D2-VASC scores were found, by
examination of registry data, to underestimate the risk ofT
ab
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thromboembolism associated with previous ischemic
events.51 Another scoring system, developed from the
Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA)
Study, identiﬁed risk stratiﬁcation schemes for bleeding and
thromboembolism to develop a simple method for quantifying
the risk of warfarin-associated hemorrhage based on 5 clinical
variables with performance comparable to the CHADS2
index.52
Registry data show that the CHA2DS2VASc score per-
formed better than CHADS2 in identifying patients at high or
low risk of thromboembolism. In general, risk stratiﬁcation
systems should be reassessed, given that new data are
developed from independent sources. A recent analysis of the
ROCKET-AF clinical trial and ATRIA cohort suggested that
renal impairment could be added to the CHADS2 score to
improve predictive value for identifying “high-risk” patients at
risk of stroke.53 Because all patients in these cohorts were at
high risk of stroke and were treated with OACs, the full range
and impact of renal function was not investigated. In another
analysis of patients across a wide spectrum of renal
impairment who were not anticoagulated, renal impairment
added little to the predictive value of the CHADS2 and
CHA2DS2-VASc scores for stratiﬁcation of thromboembolic
risk.54,55 On the other hand, renal failure patients do have a
higher risk of hemorrhagic complications,56,57 making the net
risk-beneﬁt ratio difﬁcult to establish. This is an area where
further clinical trials are needed.
OACs and stroke prevention
Multiple clinical trials established the effectiveness of the
vitamin K antagonists, compared to placebo, aspirin, other
antiplatelet agents, or no antithrombotic therapy in patients
with AF.58–61 Nevertheless, the 2006 Euro Heart Survey noted
that AF management can be inadequate, with wide variations
in physician adherence to evidence-based recommendations
for anticoagulation.6 In 2013, the EORP-AF General Registry
Pilot program showed improved uptake of OACs by European
cardiologists, with OACs prescribed for 80% of patients with
AF.32 Registry data have provided information regarding
patterns of OACs across various health systems at the
primary care,20,60 hospital,8 network,62 national,63,64 and
international21,58 hospital,7 network,59 national,60,61 and
international6,24 levels. Treatment trends over time can be
used to project resource utilization and facilitate planning of
health services and resources.
National prescribing registries suggest systematic underuse
of warfarin,65 and data from national registries of AF patients,
such as the Japanese J-RHYTHM registry, indicate warfarin
underutilization in patients at high stroke risk, as well as
overuse of warfarin in patients at low risk.9 In contrast, the Euro
Heart Survey found that OAC prescribing for AF was relativelyTa
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high throughout all risk categories and noted that this placed a
large proportion of patients with low risk of thromboembolism
at higher risk of bleeding complications.6 Frequent OAC
prescribing may relate to the relatively high proportion of
academic and specialized centers participating in this study.
Registry data from the National Cardiovascular Data Registry’s
Acute Coronary Treatment and Intervention Outcomes Net-
work (ACTION) Registry–Get with the Guidelines program also
suggest that the patients at highest risk of ischemic stroke are
least likely to take OAC medication,4 again highlighting the
need for practice improvement and compliance to ensure the
best outcomes among patients with AF. These data on
utilization could be gleaned only from registries. Data from a
number of registries providing information on the use of
warfarin, NOACs, and aspirin are shown in Table 5.
The PREFER-AF Registry found that OACs are now much
more widely used than was reported in the German AFNET
and the Euro Heart Survey registries on AF, and that NOACs
are used by 6.1% of patients with AF.13
The increasing number of registries established in recent
years to follow trends and outcomes linked to the NOACs—
such as GARFIELD, GLORIA-AF, PREFER-AF, and Randomized
Evaluation of Long-Term Anticoagulation Therapy (RE-LY)—
will continue to highlight practice variations in diverse
healthcare settings and patient populations. For example, in
the RE-LY trial, dabigatran at 150 mg (but not 110 mg) twice-
daily was associated with lower rates of stroke, compared to
warfarin.66 These variations may provide targets for improve-
ment of OAC uptake and optimize available treatment options
according to patient proﬁles. In addition to generating
pharmacoepidemiological data on OAC use, these registries
capture and assess treatment outcomes, speciﬁcally the
incidence of bleeding and persistence of therapy (including
discontinuation, interruption, and changes of therapy
regimen).
Registries may offer insights into the off-label use of OAC
drugs. The safety and efﬁcacy of periprocedural dabigatran in
patients undergoing AF ablation was evaluated in a multicen-
ter registry35 (Table 3), in which dabigatran was associated
with a signiﬁcant increase in the risk of bleeding and
thromboembolism compared to uninterrupted warfarin ther-
apy, although different lengths of time on treatment con-
founds interpretation of these observations. Two other
systematic reviews showed no differences in bleeding or
thromboembolism with periprocedural dabigatran versus
warfarin in patients undergoing ablation.67,68 Given these
Table 5. Registries Providing Information on Medical Treatment of AF
Registry
Rate-Control
Treatment (%)
Rhythm-Control
Treatment (%) Warfarin (%) NOACs (%) Aspirin (%)
AVAIL4 — — 49.1 — 5.5
CAPTURE5 — — 4.73 — —
J-RHYTHM9 — — 87.3 — 22.3
Nationwide Danish study11 — — 17.6 — —
ORBIT-AF12 — — — — 35
PREFER AF (Daiichi-Sankyo)13 — 59.8 34.1 6.1 19.8
REACH14 — — 36.2 — 42.6
RE-LY15 — — 32 — —
Swedish AF Cohort17 — — 40 — —
Euro Heart Survey6 — — 60.9 — 30.5
National Cardiovascular
Data Registry’s ACTION
Registry–Get With the
Guidelines10
— — 32.5 on admission
(41 at discharge)
— 51.5 on admission
(95 at discharge)
AFFECTS18,19 36 64 58.7 at enrollment
(63.7 at follow-up)
— 27.2 at enrollment
(31.8 at follow-up)
ATRIUM20 75 16 93.0 — —
MADRE23 — 100 — — 71
REALISE-AF24 32.7 57.5 42 — —
RECORDAF25–27 45.1 54.9 — — 43
Prospective registry35 — — 50 50 (dabigatran) 44
ACTION indicates Acute Coronary Treatment and Intervention Outcomes Network; AF, atrial ﬁbrillation; NOAC, new oral anticoagulant.
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contradictory results, more data are needed. Whereas registry
data can point to potential new approaches to management,
investigation in a controlled trial is the preferred way to
compare therapeutic strategies and provide robust, reliable
evidence with which to inform practice.
Registries on AAD Therapy and Cardioversion
Among the registries listed in Table 2, the RECORD-AF
registry involving 21 countries worldwide provides insight
into the use of AADs, factors affecting progression from
paroxysmal to persistent or permanent AF, and reveals the
extent to which clinical practice follows practice guide-
lines.26,27,69 RECORD-AF reported an overall success rate of
54% for antiarrhythmic therapy, 60% success for maintenance
of sinus rhythm, and 47% for maintaining the heart rate at or
below 80 beats per minute at 1 year.25 Key clinical outcomes
reported for rate control and rhythm control strategies at
1 year are shown in Table 6. The data suggest that clinical
outcomes of AF are driven by arrhythmia-related hospitaliza-
tion, rather than rate or rhythm management strategy,25 but
in patients assigned to rate control, there was relatively rapid
progression from paroxysmal to persistent AF. In RECORD-AF,
use of digoxin in patients without HF was uncommon,
especially in North America, and amiodarone was used
infrequently, except in patients with HF. One-year ﬁndings
from the related RECORD-AF Asia Paciﬁc registry showed that
rhythm control strategies were often applied to patients with
persistent AF and a history of HF or valvular heart disease
(37% of patients), and rate-control strategies to patients with
recently identiﬁed, paroxysmal AF (63%).28 Patients in the
rhythm-control group were prescribed class Ic (39%) or III
(49%) AADs, with lower use of b-blockers in this group in the
Asia Paciﬁc registry (35%) compared with the global RECORD-
AF registry (51%).
A number of registries provide insight into changing AF
management practices that reﬂect the availability of new
agents and updated practice guidelines. For example, CARAF
charted the use of antiarrhythmic and atrioventricular-nodal
blocking drugs from 1991 to 2007 and showed a peak in AAD
use in 1994 (42.5%), followed by a gradual decline, whereas
use of rate-controlling medications, particularly b-blockers,
increased (52.5% in 2007).21 Data from a number of registries
providing information on the use of rhythm- and rate-control
treatments are shown in Table 5. The AFFECTS registry
assessing patterns of care in the United States showed that
most ﬁrst-line therapies were aligned with the 2006 American
College of Cardiology (ACC)/American Heart Association
(AHA)/European Society of Cardiology guidelines.18,19 In
AFFECTS, rhythm-control treatment was prescribed for 67%
of patients with paroxysmal AF and 55% of patients with
persistent AF and was more often the initial treatment
strategy for older patients. The ATRIUM registry suggested
that AF therapies used by primary care providers in Germany
did not stabilize patients enough to avoid hospitalization.20
Rhythm control was used in approximately one third of
patients, often in combination with rate control, and almost all
patients received antithrombotic therapy. A comparison of the
costs associated with rhythm- versus rate-control strategies
in Quebec, Canada, found no signiﬁcant differences overall.70
The most commonly used AADs have limited efﬁcacy to
restore sinus rhythm and carry the risk of proarrhythmic
toxicity, especially in elderly patients with structural heart
disease. Registries provide information on outcomes associ-
ated with AAD use in clinical practice. The Nationwide Danish
study examined the mortality rate associated with AAD
A
B
Figure. Net clinical beneﬁt of warfarin and new oral anticoag-
ulants dabigatran, apixaban, rivaroxaban by CHA2DS2-VASC and
HAS-BLED scores. A, HAS-BLED ≤2. B, HAS-BLED ≤3. For HAS-
BLED ≥3, there were no data with CHA2DS2-VASC score=0. D110,
dabigatran 110 mg (twice-daily; BID); D150, dabigatran 150 mg
BID. Modeling was based on recent clinical trial outcome data for
the new oral anticoagulants and “real-world” data from the Danish
National Patient Registry, collected from patients with nonvalvular
AF between 1997 and 2008 to predict the net clinical beneﬁt of
new oral anticoagulants, compared to warfarin. Reproduced with
permission from Banerjee et al.11 AF indicates atrial ﬁbrillation.
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therapy in patients with AF hospitalized between 1995 and
2004.71 In this unselected cohort, treatment with ﬂecainide,
propafenone, sotalol, or amiodarone was not associated with
increased risk of death, compared to treatment without AADs,
even during the ﬁrst 30 days when risk is usually highest.
Registries assembled by regulatory agencies, such as the
U.S. Food and Drug Administration (FDA) Mini-Sentinel
program and the U.S. Department of Defense database,
reported lower all-cause mortality with dronedarone than with
other AADs.72 Population-based administrative databases are
able to provide information from a large general population of
patients with AF, with longer follow-up than is possible in
most RCTs. The FDA Mini-Sentinel program aims to detect
and reﬁne safety signals for marketed medical products and
additionally identify algorithms used within administrative
databases to detect and analyze health outcomes for patients
with AF.73 This registry suggests that a substantial proportion
of the variation in AF prevalence across studies may be the
result of the choice of different criteria for conﬁrming AF. A
systematic literature review was performed to characterize
the validity of algorithms to identify patients with AF from
electronic health data.74 Use of nonrepresentative popula-
tions, a paucity of recent data, and a disproportionate focus
on data from inpatients hindered conclusions about algorithm
validity, and the researchers advised that additional research
is needed in contemporary representative populations.
Follow-up of patients in registries can track AF recurrence,
although inferences require conﬁrmatory evidence from
clinical trials. In the MADRE registry, dronedarone was
administered for rhythm control in a small cohort of patients
followed for 300 days. AF recurrence was common (66.5%),
suggesting that dronedarone may not be superior to other
AADs in maintaining sinus rhythm.23 Outcomes among
ambulatory patients, drawn from the cross-sectional REA-
LISE-AF survey, showed that the target heart rate was not
achieved in 71% of the cases in which a rate-control strategy
was chosen, whereas 26% of those selected for a rhythm-
control strategy found that AADs failed to maintain sinus
rhythm.6 Overall, 44% of patients with controlled AF were
asymptomatic. Results from REALISE-AF highlight that guide-
lines for use of AADs are not closely followed, and alternative
therapies are needed to improve CV outcomes in patients
with AF.
Table 2 highlights country-to-country differences in elec-
trical versus pharmacological cardioversion practice, with
RHYTHM-AF showing a preference for direct-current cardio-
version at academic centers in Germany, where there is ease
of access and a generally high primary success rate.30
Electrical cardioversion is also a common choice in Sweden,
whereas pharmacological cardioversion is more often chosen
in Spain.
Registries on AF Ablation
Catheter-based pulmonary vein isolation for AF ablation,
introduced more than 2 decades ago, is viewed today as a
reasonable therapeutic option to prevent symptomatic AF in
patients refractory to, or intolerant of, antiarrhythmic medi-
cation.26 Although several small randomized trials of AF
ablation of AF showed signiﬁcantly higher rates of freedom
from AF with ablation, compared to AADs, this reﬂects
outcomes in highly selected patients performed by experi-
enced operators. Some were single-center studies, follow-up
was generally limited to 12 months, and monitoring for
recurrent AF varied considerably.25,26,75
Given the limitation of these trials, registry data offer
important insights into the application, success, and limita-
tions of ablation therapy (Table 3). The AF ablation pilot study
Table 6. Key Clinical Outcomes Reported in the RECORD-AF Registry at 1 Year25
Clinical Events Rhythm Control (%) Rate Control (%) P Value
Any clinical event 483/2809 (17.2) 405/2225 (18.2) 0.352
Cardiovascular death 24/2804 (0.9) 61/2213 (2.8) <0.001
Myocardial infarction 14/2785 (0.5) 20/2175 (0.9) 0.078
Stroke or transient ischemic attack 46/2784 (1.7) 60/2179 (2.8) 0.008
Hospitalization for cardiovascular event 465/2793 (16.6) 366/2195 (16.7) 0.891
Hospitalization or increased duration of hospital stay
Due to arrythmia or proarrhythmia 314/2790 (11.3) 159/2179 (7.3) <0.001
Due to other cardiovascular events or interventions 190/2791 (6.8) 204/2182 (9.3) 0.001
Due to major complications of ablative procedure 15/2786 (0.5) 14/2171 (0.6) 0.626
Occurrence of clinical outcomes was counted between baseline and 12 months in patients with AF or a history of AF, excluding permanent AF or transient/reversible causes of AF.
Cardiovascular death recorded at 12 months includes any events reported until the end of the 15th month after baseline. AF indicates atrial ﬁbrillation; RECORD-AF, The global Registry on
Cardiac rhythm disorders assessing the control of Atrial Fibrillation.
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of the European Heart Rhythm Association, the ﬁrst system-
atic, prospective international study speciﬁcally aimed at
collecting information on AF ablation practices in Europe,
suggests that patients selected for ablation are younger and
more symptomatic of the arrhythmia, with up to one third
seeking to reduce or eliminate the need for medications.31
This preliminary study showed that the most commonly
employed ablation strategy is electrical isolation of the
pulmonary veins and that, at discharge, 91.4% of patients
were in sinus rhythm and 88.3% of patients were receiving
vitamin K antagonists and 67% AADs. After 1 year, of 944
patients, 73.7% were free of recurrent AF based on periodic
ECG monitoring, 56.6% without AADs, and conduction block
was present in approximately 60%.31 The overall complication
rate was 7.7%, in the range of other multicenter surveys.76
Other insights come from a world-wide survey of catheter
ablations that focused on methodology, rather than patient
characteristics and outcomes. In this survey, success rates
were higher in patients with paroxysmal than persistent and
long-standing AF, and 70% of patients did not require further
AAD treatment during follow-up.77 Reports from Canada of
the costs, compared to medical therapy, for paroxysmal AF
found catheter ablation a ﬁscally viable alternative, with cost
equivalence after 4 years.78 LAAC devices, such as the ACP
and the Watchman device, have been proposed as alterna-
tives to anticoagulation in patients at high risk of stroke
(Table 4).
The Future of AF Registries
Currently available registries are providing a wealth of data
that will help guide management of AF patients. Trial data
have conﬁrmed the effectiveness of novel anticoagulants,
including dabigatran, rivaroxaban, apixaban, NOACs and
edoxaban,65,79–81 and other agents may be introduced in
the future. Efforts are underway to address the comparative
effectiveness of these agents,11,82,83 but ongoing registry
data will establish evolving clinical practices regarding their
use relative to warfarin and one another.4,15 Another impor-
tant function of longitudinal registries is to identify safety
concerns surrounding these agents.
Registry data can have important limitations that should
not be overlooked. Among these are data from single centers
involving short follow-up in which patient demographics and
patterns of AF are not well characterized. Unlike RCTs, which
include highly selected patients that limit generalizability,
registries are population based and therefore subject to bias.
Registries lack controls from which to draw comparative
assessments. Furthermore, data are lacking for some regions,
and the majority have focused on Europe and the United
States, although studies such as RECORD-AF Asia Paciﬁc seek
to address this. It has been also suggested, by the 2014
AHA/ACC/Heart Rhythm Society guidelines for management
of patients with AF, that comparisons between registries from
different sociocultural backgrounds may be obscured by the
difﬁculty to quantify and report individualized antithrombotic
therapy based on a shared physician-patient decision.84 An
important factor to consider when studying registry data is
whether the registry is sponsored through industry, given that
this may introduce the possibility of bias into the outcomes.
Some challenges face those attempting to initiate regis-
tries, such as specifying the purpose of the registry early on,
how the data will be used, who will analyze it, who will have
access to it, and, most important, who will fund it.36,85 This
information can, for example, determine whether patients in
the registry are similar to those enrolled in RCTs, generate
hypotheses for future clinical trials, and determine the
effectiveness of therapy in subpopulations. Obtaining sufﬁ-
cient funding for a registry is also a critical challenge. Previous
registries have been either voluntary or linked to reimburse-
ment.36 Determining the best funding mechanism for a
registry early on is one of the most critical ﬁrst steps to the
success of such a registry. Investment in a national registry
certainly requires substantial resources. Such investments
must be balanced with other important safety and clinical
effectiveness studies, such as CABANA and EAST.36,86
AF typically coexists with other conditions as both risk
factors and complications. Registry data can inform our
knowledge of the relationship between AF and other diseases
to facilitate tailored, patient-speciﬁc approaches.
Conclusions
As highlighted in this review, registries extend knowledge of
the natural history, risk factors, treatment practices, and long-
term outcomes and risks of management strategies within a
truly representative population of AF patients managed in
clinical practice. Together with patient database evaluations,
these resources can greatly improve understanding of the
needs and gaps in care for diverse patient subgroups. Though
a comprehensive review of administrative databases was not
within the scope of this review, increasingly relevant literature
derived from mining of patient data can inform the manage-
ment of patients with AF in an array of care settings.
Registry data are the means by which to determine
whether patients are managed in line with evidence-based
guidelines—but they offer more than just a reﬂection of
whether everyday practice adheres to accepted norms or
ideals. Follow-up of large numbers of patients allows assess-
ment of long-term outcomes and infrequent complications.
There is scope to gather more information on the impact of AF
and its management on quality of life as well as to provide
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insights into the overall health economic burden of AF. These
registries have already helped shape and improve the way we
manage patients, and well-designed registries have the
potential to yield hypotheses to guide future clinical and
basic research.
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